Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIAT
Ratios

Cullinan Therapeutics (CGEM) EBIAT (2020 - 2023)

Cullinan Therapeutics has reported EBIAT over the past 4 years, most recently at -$23.6 million for Q4 2023.

  • Quarterly results put EBIAT at -$23.6 million for Q4 2023, up 5.76% from a year ago — trailing twelve months through Dec 2023 was -$153.2 million (down 237.72% YoY), and the annual figure for FY2025 was -$219.9 million, down 31.21%.
  • EBIAT for Q4 2023 was -$23.6 million at Cullinan Therapeutics, up from -$39.2 million in the prior quarter.
  • Over the last five years, EBIAT for CGEM hit a ceiling of $174.1 million in Q2 2022 and a floor of -$58.1 million in Q1 2023.
  • Median EBIAT over the past 4 years was -$19.4 million (2020), compared with a mean of -$9.8 million.
  • Peak annual rise in EBIAT hit 1158.85% in 2022, while the deepest fall reached 1008.53% in 2022.
  • Cullinan Therapeutics' EBIAT stood at -$21.4 million in 2020, then tumbled by 51.6% to -$32.5 million in 2021, then increased by 22.9% to -$25.1 million in 2022, then increased by 5.76% to -$23.6 million in 2023.
  • The last three reported values for EBIAT were -$23.6 million (Q4 2023), -$39.2 million (Q3 2023), and -$32.2 million (Q2 2023) per Business Quant data.